Search results for "phases"
showing 10 items of 282 documents
Solid Phases as Protective Environments for Biomimetic Catalysts
2014
THE PERFORATED BUILDING’S ENVELOPE: GUIDING THE EARLY DESIGN PHASES
In passato gli involucri edilizi perforati sono stati talvolta ricondotti ad alcuni elementi architettonici tradizionali (come, ad esempio, la ‘Mashrabiyya’), in cui gli elementi forati acquisiscono quasi significati archetipici, nell’assumere ruoli tecnologici e ambientali che rispecchiano i valori della comunità, le condizioni socio-economiche e le esigenze ambientali degli occupanti. Oggi, invece, l’involucro edilizio perforato costituisce una tendenza architettonica che ha iniziato a manifestarsi a livello globale all’inizio del nuovo millennio, alla quale ha contribuito l’emergere della tecnologia digitale con i suoi effetti sull’innovazione di tecniche, materiali, realizzazioni, prest…
90Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II…
2016
Abstract Purpose Updated 5 year results are presented from the multicenter phase II trial of 90Yttrium-Ibritumomab-Tiuxetan (90YIT) as first line stand-alone therapy for patients with follicular lymphoma (FL). Patients and Methods 59 patients with CD20-positive FL grade 1 to 3a in stages II with bulky disease (n=12), III (n= 26), or IV (n=21), and in need for therapy, were enrolled between 05/2007 and 06/2010. They received 90YIT according to standard procedure (rituximab 250 mg/m2 days -7 and 0, then 90YIT 15 MBq/kg (0.4mCi/kg) day 0; patients with platelet counts below 150.000/ul but above 100.000/ul received only 11 MBq/kg). Primary end point was the clinical and molecular remission rate…
Reliability of measurements during countermovement jump assessments: Analysis of performance across subphases
2020
The aim of this study was to examine the reliability of performance measures in the different phases and sub-phases of the countermovement jump (CMJ). Seventeen male athletes competing at a regional level completed 204 valid trails consisting of the execution of maximal hands-on-waist CMJs performed on a force platform. The vertical ground reaction force (VGRF) data obtained at a sampling frequency of 1000 Hz were used to calculate performance-derived variables and determine key points and jump sub-phases. The relative reliability of 92 variables was assessed using the intraclass correlation coefficient (ICC) from a two-way mixed effects model analyzing the time, force, power, velocity, and…
Personalizzazione e orientamento per una didattica inclusiva. Il processo di ricerca, le azioni di ricerca.
2017
Sono presentati gli obiettivi, le ipotesi e le modalità di verifica delle nove azioni in cui si è articolato il progetto di rilevante interesse nazionale realizzato dall’unità di ricerca dell’Università di Palermo tra il 2013 e il 2016. Il contributo evidenzia in che modo le nove azioni di ricerca hanno contribuito a realizzare una didattica inclusiva partendo dal presupposto della personalizzazione dell’insegnamento. L’autore, in qualità di coordinatore dell’unità locale di ricerca, mostra il filo rosso che unisce tra loro le diverse azioni di ricerca che si sono svolte parallelamente in Sicilia e le collega con le finalità dell’intero progetto nazionale. The objectives, hypotheses and pro…
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled rando…
2019
Abstract Background Hereditary angioedema (HAE) is a debilitating disorder resulting from C1-esterase inhibitor (C1-INH) deficiency. In the COMPACT phase 3 study the prophylactic use of a subcutaneous C1 inhibitor (C1-INH [SC], HAEGARDA®, CSL Behring) twice weekly significantly reduced the frequency of acute edema attacks. Analysis of treatment effects by subgroups, onset of effect, and other exploratory analysis have not been reported. Methods This is a post hoc exploratory analysis on data from the randomized, placebo-controlled COMPACT study. 90 patients with C1-INH-HAE were randomized to 1 of 4 treatment sequences: C1-INH (SC) 40 or 60 IU/kg of body weight twice weekly for 16 weeks, pre…
Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with acute lymphoblastic leukemi…
2014
Abstract Total-body-irradiation (TBI) based preparative regimens are considered as standard conditioning therapy for allogeneic stem cell transplantation (AHSC) in patients with acute lymphoblastic leukemia (ALL). Within a multi-center prospective phase II study we have investigated the toxicity and efficacy of a non-TBI-based regimen consisting of treosulfan, etoposide, and cyclophosphamide in patients with ALL. Inclusion criteria were complete remission, non-eligibility for TBI or patient’s wish to avoid TBI. Between July 2007 and August 2010, 50 patients with a median age of 46.5 years were enrolled at ten German centers. 74% of the patients were in 1. CR and 26% 2. or higher CR.The cond…
Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: The FFCD 1104-EVACEL-GTE phase II study
2018
Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DA…
2016
Abstract Background: While first line therapy for FL with chemotherapy or chemoimmunotherapy produces durable responses, most patients (pts) with FL eventually relapse. Those who become resistant to chemoimmunotherapy have limited treatment options. Ibrutinib, an inhibitor of BTK (Bruton's tyrosine kinase) and ITK (interleukin-2-inducible T-cell kinase), has demonstrated robust clinical activity in various B-cell non-Hodgkin lymphomas. Previous Phase 1 and 2 studies have shown promising results with single-agent ibrutinib in pts with relapsed or refractory FL (Bartlett NL. Blood. 2014; 800 & Fowler N. Blood. 2015; 2706). The aim of the DAWN study was to provide additional efficacy and s…
Efficacy and Safety of Multiple Doses of Imab362 in Patients with Advanced Gastro-Esophageal Cancer: Results of a Phase Ii Study
2014
ABSTRACT Aim: IMAB362 is a monoclonal antibody specifically targeting claudin 18 isoform 2 (CLDN18.2), which is expressed on gastric cancer cells, whereas it is only present on a fraction of healthy stomach cells. This may reduce the risk of target-related side effects. Single-agent IMAB362 appears safe in patients with advanced gastro-esophageal cancer (GEC) based on data from a phase I trial. Methods: This international, multicenter, non-randomized phase IIa study (NCT01197885) investigated the efficacy and safety of repeated doses of IMAB362 (300 and 600 mg/m2) in patients with metastatic, refractory/recurrent, CLDN18.2-positive GEC (i.e. cancer of the stomach, the lower esophagus and th…